Anadys Pharmaceuticals (ANDS) 10-Q 2006 Q2 Quarterly report

Exhibit 32

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND VICE PRESIDENT, FINANCE PURSUANT TO 18 U.S.C.
SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. Section 1350, as adopted), Kleanthis G. Xanthopoulos, Ph.D., as President and Chief Executive Officer of the Company, and Jennifer K. Crittenden, as Vice President, Finance of the Company, each hereby certifies that, to the best of his or her knowledge:

     1. The Company’s Quarterly Report on Form 10-Q for the six months ended June 30, 2006, to which this Certification is attached as Exhibit 32 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

     2. The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Quarterly Report and results of operations of the Company for the periods covered by the Quarterly Report.

/s/ Kleanthis G. Xanthopoulos, Ph.D.	/s/ Jennifer K. Crittenden
Kleanthis G. Xanthopoulos, Ph.D.	Jennifer K. Crittenden
President and Chief Executive Officer	Vice President, Finance
Date: August 9, 2006	Date: August 9, 2006